<ul><li>Carlyle, SK Capital Partners, LP, and Beacon Parent Holdings, L.P. announced a tender offer on March 7, 2025, to acquire all outstanding common stock of bluebird bio, Inc. for either $3.00 per share in cash and a contingent value right, or $5.00 per share in cash.</li><li>The tender offer expired on May 29, 2025, without an extension. The acquisition is expected to be completed on June 2, 2025, through a merger of Merger Sub with bluebird, in accordance with the terms of the Merger Agreement.</li><li>The merger will be executed under Section 251(h) of the General Corporation Law of the State of Delaware without requiring a vote of bluebird stockholders.</li><li>On Friday, CG shares fell by 1.9% to $44.97, and BLUE shares decreased slightly to $4.96.</li></ul>

Carlyle Expects bluebird Deal to be Concluded Soon

Discover more